Abstract

Dr. Eddie Martucci, a biomedical scientist and entrepreneur, has played a transformative role in redefining treatment approaches for pediatric Attention Deficit Hyperactivity Disorder (ADHD) through digital therapeutics. As the co-founder and CEO of Akili Interactive, he spearheaded the development of EndeavorRx, the first FDA-authorized prescription video game designed to enhance attention in children aged 8–12 years with ADHD. Grounded in neuroscience, the therapy utilizes adaptive algorithms and multisensory stimuli to target cognitive control networks in the brain. Martucci’s work is notable not only for its scientific innovation but also for introducing a non-pharmacological, child-friendly treatment option with minimal side effects. Clinical trials, including randomized controlled studies published in The Lancet Digital Health, have demonstrated significant improvements in attention, validating the therapeutic potential of digital interventions. Despite initial skepticism from clinicians, regulatory challenges, and limited investor confidence, Martucci’s persistence led to a landmark FDA authorization in 2020, establishing a new paradigm for software-based medicine. His contributions highlight the importance of interdisciplinary collaboration between neuroscience, game design, and clinical science. This article reviews Martucci’s background, scientific contributions, challenges faced, and the broader implications of digital therapeutics for future ADHD care, underscoring his role in reshaping pediatric mental health treatment. Key Messages: Digital therapeutics, exemplified by Dr. Eddie Martucci’s FDAapproved video-game treatment EndeavorRx, represent a revolutionary shift in pediatric ADHD management. By combining neuroscience with adaptive interactive technology, these innovations offer an effective, non-pharmacological, child-friendly alternative that enhances attention, reduces stigma, and redefines the future of cognitive healthcare. Dr. Martucci’s work demonstrates how interdisciplinary science, rigorous clinical validation, and patient-centred design can transform mental-health treatment for the youngest and most vulnerable

• 1.   Kollins Scott H., DeLoss Denton J. A novel digital intervention for actively reducing severity of Pediatric ADHD (STARS-ADHD): a randomised controlled trial. The Lancet Digital Health 2020; 2(4): e168-e178.
• 2.   Gallen Courtney L., Marco Elysa, Anguera Joaquin A., et al. Enhancing neural markers of attention in children with ADHD using a digital therapeutic. PLOS One 2021; 16(12): e0261981.
• 3.   Oh SuA, Choi Jina, Han Doug-Hyun, Kim EunYoung. Effects of game-based digital therapeutics on attention deficit hyperactivity disorder in children and adolescents as assessed by parents or teachers: a systematic review and meta-analysis. European Child & Adolescent Psychiatry 2025; 33(3): 481-493.
• 4.   He F., … (et al.) Meta-analysis of the efficacy of digital therapies in children with ADHD. Frontiers in Psychiatry 2023; 14: 1054831.
• 5.   Catalá-López F., Macías Saint Gerons D., GarcíaPérez L., et al. Digital health interventions for children with ADHD. The Lancet Digital Health 2020; 2(8): e364- e375.
• 6.   Gabarron E., Serrano I., Martínez de la Iglesia A., et al. Evaluating the evidence: A systematic review of reviews of the effectiveness of digital interventions for ADHD. BMC Psychiatry 2025; 25(1): 68.

Data Sharing Statement

Funding